ClinicalTrials.gg
RecruitingNCT07488052HOME-ECGUpdated Mar 25, 2026

Home-based Outpatient Multicenter Evaluation Using Electrocardiogram (HOME-ECG)

An observational study in Heart Failure, sponsored by National Defense Medical Center, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by National Defense Medical Center, Taiwan · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
20 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 137 studies in Heart Failure with a site in Taiwan — 30 open to participants now, 39 under way, 14 of them phase 3. Heart Failure · Taiwan.

Planned enrollment
5th of 36
5,000 · median 200
Started
2026
with 9 others
Observational
36 of 137
5 open now
Primary completion
2026-06
later than 11 of 38 live
Registered
131st of 137
by date

Among the 137 studies in Heart Failure with a site in Taiwan, this one is the 5th largest by planned enrollment of the 36 observational ones that give a count, is one of 10 that started in 2026, is one of 36 observational ones, reaches primary completion later than 11 of the 38 other live ones, and was the 131st registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

30 of the 137 studies in Heart Failure with a site in Taiwan are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 20 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Heart Failure with a site in Taiwan, or all of them as a file.
02

Study summary

This prospective multicenter observational study will validate the accuracy of a previously developed artificial intelligence-enabled single-lead electrocardiogram (AI-ECG) model for identifying low ejection fraction and other structural heart disease phenotypes. Adult participants receiving a model-compatible single-lead electrocardiogram (ECG) (Apple Watch and QOCA ECG102D) and transthoracic echocardiography at five hospitals in Taiwan will be enrolled between March 1, 2026 and June 30, 2026. Model predictions will be compared with echocardiographic reference standards obtained within 30 days after the index ECG.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Consecutive adult participants undergoing model-compatible single-lead ECG acquisition and paired echocardiographic assessment at five participating hospitals (Taipei Medical University WanFang Hospital; Far Eastern Memorial Hospital; Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation; Chi Mei Medical Hospital; and China Medical University Hospital) in Taiwan during the prospective enrollment period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 20 years or older
  • Single-lead recorded using a study-compatible device
  • Ability to comply with study procedures and, when applicable, provide according to local institutional review board (IRB) requirements
  • No transthoracic echocardiography performed within 90 days before the index ECG

Exclusion criteria

Exclusion Criteria:

  • signal quality insufficient for prespecified AI analysis
  • No transthoracic echocardiography available within 30 days after the index ECG
  • Echocardiography unavailable or technically inadequate for determining (EF)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Prospective Validation Cohort

    Adults enrolled at participating hospitals who undergo model-compatible single-lead ECG acquisition and reference transthoracic echocardiography for prospective validation of AI-ECG models for low ejection fraction and structural heart disease.

    Diagnostic Test: Single-Lead ECG Acquisition [Apple Watch and QOCA ECG102D]

Interventions

  • Diagnostic testSingle-Lead ECG Acquisition [Apple Watch and QOCA ECG102D]

    A single-lead Lead-I ECG recorded using a device compatible with the prespecified AI-ECG pipeline and analyzed offline by the locked AI model.

06

What researchers measure

Primary outcomes

  1. Area Under the Receiver Operating Characteristic Curve for Detection of Low Left Ventricular Ejection Fraction

    AUC with 95% confidence interval for detection of low EF, defined as echocardiographic LVEF ≤40%, by the pre-specified AI-enabled single-lead ECG model.

    Time frame: 30 days

  2. Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value for Low EF Detection at the Pre-specified Operating Threshold

    Diagnostic operating characteristics of the locked AI model for low EF at the pre-specified threshold.

    Time frame: 30 days

Secondary outcomes

  1. Positive Predictive Value and Negative Predictive Value for Structural Heart Disease at the Pre-specified Operating Threshold

    Prevalence of structural heart disease in patients identified as positive and negative by AI-ECG for detecting low EF, including left atrial enlargement, valvular heart disease, pulmonary hypertension, left ventricular hypertrophy, etc.

    Time frame: 30 days

  2. Difference in All-Cause Mortality Risk at the Pre-specified Operating Threshold

    All-cause mortality risk in patients identified as positive and negative by AI-ECG for detecting low EF.

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
  • Taipei Medical University WanFang Hospital; Far Eastern Memorial Hospital; Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation; Chi Mei Medical Hospital; and China Medical University Hospital
    Taipei, 114, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data are not planned for public sharing. Aggregate summary results may be reported in publications and registry updates.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2026, 3 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 3 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 23, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07488052
Lead sponsor
National Defense Medical Center, Taiwan
Collaborators
Taipei Medical University WanFang Hospital, Far Eastern Memorial Hospital, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chi Mei Medical Hospital, China Medical University Hospital
Responsible party
Chin Lin (Professor, National Defense Medical Center, Taiwan) — Principal investigator
First posted
Mar 23, 2026
Start date
Mar 1, 2026
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Mar 25, 2026

Study contacts

CHIN LIN, PhD
Contact
xup6fup0629@gmail.com
+886958259269
CHIN LIN, PhD
principal investigator · National Defense Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion